Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CPX-351 (Cytarabine:Daunorubicin) Liposome Injection
CPX-351 Liposome · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CPX-351 (Cytarabine:Daunorubicin) Liposome Injection | DRUG | - |
Inclusion Criteria: * Ability to understand and voluntarily sign an informed consent form * Age \> 18 years at the time of signing the informed consent form * Pathological confirmation of leukemia or myelodysplastic syndrome. * AML according to WHO criteria; except for core-binding factor AMLs (t(8...
CPX-351 Liposome is an investigational small molecule therapy developed for hematologic neoplasms, a group of blood cancers. It was studied in a single Phase 1 multicenter trial of 48 patients with advanced hematologic cancer in the United States. It is also known as CPX-351 (Cytarabine:Daunorubicin) Liposome Injection.
CPX-351 Liposome was studied for the treatment of hematologic neoplasms, specifically in patients with advanced hematologic cancer. The clinical program enrolled adults aged 18 years and older of any sex. The trial was conducted in the United States and has been completed.
CPX-351 Liposome is developed by Jazz Pharmaceuticals plc, which trades on the Nasdaq under the ticker JAZZ. Jazz Pharmaceuticals sponsored the Phase 1 multicenter study of the agent in patients with advanced hematologic cancer.
CPX-351 Liposome is in Phase 1 clinical development. It is an investigational agent and is not described as approved. One Phase 1 trial has been completed, and no trials are currently active. That study enrolled 48 patients with advanced hematologic cancer.
CPX-351 Liposome was evaluated in the Phase 1 trial NCT00389428, titled a multicenter study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with advanced hematologic cancer. The trial enrolled 48 adults, was uncontrolled, was not randomized or double blinded, and has been completed.
Yes. CPX-351 Liposome and CPX-351 (Cytarabine:Daunorubicin) Liposome Injection refer to the same investigational agent. The full name describes the liposomal formulation containing cytarabine and daunorubicin. Both names appear in the Phase 1 trial record NCT00389428 in advanced hematologic cancer.